BEGIN:VCALENDAR
VERSION:2.0
PRODID:-// - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://paradigms.foundation
X-WR-CALDESC:Events for 
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20260429T173000
DTEND;TZID=Europe/Paris:20260429T183000
DTSTAMP:20260421T123350
CREATED:20260413T084357Z
LAST-MODIFIED:20260413T155125Z
UID:13900-1777483800-1777487400@paradigms.foundation
SUMMARY:Live Webinar on the long-term efficacy and safety of anti-CD20 therapies
DESCRIPTION:Anti-CD20 therapies have become a central component in the management of Multiple Sclerosis (MS)\, with growing evidence supporting their sustained use. In this live webinar\, Celia Oreja-Guevara and Patrick Vermersch will review long-term efficacy and safety data\, translating current evidence into practical insights for neurologists involved in treatment decisions. \n\n\n\n \n\n\n\nKey Highlights\n\n\n\n\nReview long-term efficacy data of anti-CD20 therapies in Multiple Sclerosis (MS) \n\n\n\nAssess safety profiles with extended treatment exposure \n\n\n\nDiscuss risk–benefit considerations in long-term disease management \n\n\n\nExplore real-world evidence and its implications for clinical practice \n\n\n\nAddress monitoring strategies and patient selection over time \n\n\n\nGain expert perspectives on optimizing treatment decisions\n\n\n\n\nRegister to access the webinar\n\n\n\nThis session will be held live on Zoom. We warmly encourage you to register in advance to secure your place and take part in the exchange of knowledge and discussions. \n\n\n\n\nRegister to access the webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages\, offered by Zoom platform. \n\n\n\nThis webinar might interest you if you are:\n\n\n\n\nNeurologists with a particular interest in multiple sclerosis therapies and treatments\n\n\n\nNeurologists in training\n\n\n\nNurses engaged in the care of patients with multiple sclerosis\n\n\n\nPatient representatives\n\n\n\n\nQuestions and discussion\n\n\n\nIf there are specific questions you would like to see addressed during the session\, we encourage you to share them in advance at learning@paradigms.foundation. This will allow the speakers to incorporate them into their presentations. \n\n\n\nYou will also have the opportunity to raise questions directly and actively contribute to the discussion during the webinar and the dedicated Q&A session. \n\n\n\nTechnology used\n\n\n\nThe session will be conducted via Zoom\, with access credentials shared upon completion of your registration. \n\n\n\nTime and date\n\n\n\nThe session will be held in English on Wednesday\, 29 April 2026 from 5:30 to 6:30 p.m. CET. \n\n\n\nInvited Speakers\n\n\n\n\n\n\n\nCelia Oreja-Guevara\n\n\n\nVice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos\, Madrid \n\n\n\nAfter receiving her MD from the University Complutense\, Madrid\, Professor Oreja-Guevara completed a PhD in neuroimmunology at the Max-Planck-Institute for Neurobiology\, University of Munich\, Munich (Germany). She then went on to complete a residency in the Department of Neurology at the University of Bochum\, Bochum (Germany) and a postdoctoral fellowship in neuroimaging at the University Hospital San Raffaele\, Milan (Italy). She has also held posts at the University of Düsseldorf (Germany)\,Hospital de Fuenlabrada and at the University Hospital La Paz\, both in Madrid. \n\n\n\nProfessor Oreja-Guevara’s research interests centre on family planning\, menopause\, clinical and neuroimaging correlations in MS and the use of optical coherence tomography. As an investigator\, she has participated in a number of MS clinical trials and currently heads Paradigms\, an independent and non-profit international group of Multiple Sclerosis experts. Currently\, Professor Oreja-Guevara is an expert for the Spanish Medicines Agency and for the Scientific Advisory Group on Neurology of the European Medicines Agency. \n\n\n\n\n\n\n\nPatrick Vermersch\n\n\n\nVice-president of Research in the fields of Life and Health Sciences at the University of Lille \n\n\n\nPatrick Vermersch studied medicine at Lille University Hospital (France)\, where he graduated in Neurology. Between 1990 and 1994 he pursued his training in basic research fields\, mainly in cellular biology\, obtaining a PhD addressing biochemical abnormalities associated with Alzheimer’s and other neurodegenerative diseases. He also conducted research related to the characterization of post-transcriptional anomalies of tau proteins. His research interests then turned to multiple sclerosis (MS). \n\n\n\nProf. Patrick Vermersch is head of one of the University of Lille’s departments of Neurology which deals with MS and other neuroinflammatory diseases. The department is primarily concerned with neuroimmunology and markers of disease evolution. \n\n\n\nProf. Patrick Vermersch is currently vice-president of research in the fields of Life and Health Sciences at the University of Lille. In 2000\, he and colleagues created the first MS network in northern France to improve MS care and research. His current areas of interest are prognostic markers in MS and neuroimmunology in general. He participates in many treatment protocols for MS. He has authored or co-authored approximately 380 scientific papers. His H-index (Web of Science) is 54. \n\n\n\nFunding\n\n\n\nThis webinar is organized with the financial support of Neuraxpharm.  \n\n\n\nNeuraxpharm has not been involved in the elaboration of the presentations.
URL:https://paradigms.foundation/event/live-webinar-on-the-long-term-efficacy-and-safety-of-anti-cd20-therapies/
ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/04/LAU-PROD-banner-live-webinar-sessions-260429-1200x627px.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20260613T000000
DTEND;TZID=Europe/Paris:20260613T235959
DTSTAMP:20260421T123350
CREATED:20251216T103224Z
LAST-MODIFIED:20260331T153957Z
UID:12647-1781308800-1781395199@paradigms.foundation
SUMMARY:Annual MS Meeting 2026
DESCRIPTION:Saturday\, June 13th – morning session\n\n\n\n\n\n\n\nOptic Neuritis Unveiled: Clinical and Imaging Perspectives\n\n\n\nIrish College\, Leuven\n\n\n\nThe Belgian Study Group for Multiple Sclerosis (BSGMS) and ParadigMS Foundation are pleased to announce the Annual MS Meeting 2026\, a scientific meeting for the Belgian MS community and allied healthcare professionals. \n\n\n\nThis year’s meeting\, entitled “Optic Neuritis Unveiled: Clinical and Imaging Perspectives\,” will focus on optic neuritis as a key clinical entity in multiple sclerosis and related disorders. The programme will combine clinical expertise with advanced imaging approaches\, highlighting how evolving diagnostic tools can support earlier diagnosis\, improved prognostication\, and optimized patient management. \n\n\n\nRegistration: get your ticket now!\n\n\n\n\n\n\n\n\n\n\n\nScientific Programme \n\n\n\nThe meeting will feature three keynote lectures delivered by internationally recognized experts\, followed by interactive case discussions and clinical conclusions. The exact timing will be confirmed.  \n\n\n\n\n\n\n\n \n\n\n\nAbout the co-chairs and the keynotes speakers\n        \n            \n              \n                        \n                            About the speakers\n                        \n                    \n                        \n                            About the co-Chairs\n                        \n                    \n            \n            \n                \n\n\n\n\n\n\n\nAxel Petzold (UK) is a consultant neurologist at the National Hospital for Neurology and Neurosurgery\, Queen Square\, and at Moorfields Eye Hospital in London. His clinical and research work focuses on multiple sclerosis and optic neuritis. He is a Fellow of the Royal College of Physicians\, the Royal College of Ophthalmologists\, and the Royal College of Pathologists. Over the years\, he has been involved in a number of collaborative initiatives\, including serving as Chair for Neuro-Ophthalmology within the European Reference Networks for Rare Diseases. He has also helped develop integrated care pathways between his NHS Hospital Trusts. Prof Petzold has published widely in peer-reviewed journals and has supervised and mentored fellows and students from different countries. He remains committed to careful clinical practice\, collaborative research\, and supporting the next generation of clinicians and scientists. \n\n\n\n\n\n\n\n\n\nAnne-Catherine Chapelle (Belgium) is a neuro-ophthalmologist and pediatric ophthalmologist at the University Hospital of Liège\, where she is involved in both clinical practice and academic activities. She completed a neuro-ophthalmology fellowship in London under the supervision of Professor Gordon Plant\, gaining advanced expertise in the diagnosis and management of complex neuro-ophthalmic disorders\, including inflammatory and demyelinating diseases of the visual pathway. She subsequently completed a doctoral thesis focused on retinal ganglion cell evaluation in ischemic optic neuropathies\, with particular attention to structural and functional correlations. Her clinical and research interests center on optic nerve disorders and the use of retinal imaging\, notably optical coherence tomography (OCT)\, as a biomarker in neurological diseases. \n\n\n\n\n\n\n\n\n\n\n\n\n\nJette Lautrup Frederiksen (Denmark) is Professor of Neurology\, Senior Consultant\, MD and Doctor of Medical Sciences (DMSc) at University of Copenhagen based on thesis “A prospective Study of Acute Optic Neuritis: Clinical\, MRI. CSF\, Neurophysiological and HLA Findings”. She has 40 years of research experience in the clinical\, imaging\, neurophysiological and biomedical aspects of optic neuritis\, multiple sclerosis and neuro-ophthalmology. She is the founder of the Multiple Sclerosis Clinic at Copenhagen University Hospital Rigshospitalet Glostrup\, Denmark and head of the Optic Neuritis Clinic there. Since 2011 she has been Professor in Optic Neuritis in relation to Multiple Sclerosis at the University of Copenhagen. She is by Scholar GPS ranked No. 2 within the category Optic Neuritis lifelong and has authored more than 300 publications in international scientific journals. \n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nBelgian Study Group for Multiple Sclerosis \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nParadigMS Foundation \n\n\n\n\n\n\nProf. Bénédicte Dubois (Belgium) is an internationally recognised neurologist and multiple sclerosis expert. She is Head of the Department of Neurology at University Hospitals Leuven\, Head of the Laboratory for Neuroimmunology\, and part-time Full Professor at the Faculty of Medicine of KU Leuven\, where she also leads the Research Group Experimental Neurology and oversees the medical clerkship centres. Alongside her leadership roles\, she is a pioneer of interdisciplinary MS care and precision medicine in Belgium\, and her translational research focuses on the neuroimmunological and genetic mechanisms underlying MS\, supported by a unique longitudinal patient database. She is also actively involved in multiple internal and external committees dedicated to education and scientific research. \n\n\n\nProf. Bart Van Wijmeersch (Belgium) is a neurologist specialised in multiple sclerosis and Associate Professor of Neurology at the University of Hasselt\, affiliated with the Biomedical Institute (BIOMED). He is Medical Director of the Rehabilitation and MS Center in Pelt\, where he leads a multidisciplinary MS team delivering comprehensive patient care. His academic and clinical work bridges immunological\, biomarker\, MRI\, electrophysiological\, and rehabilitation research in MS\, combining pre-clinical models\, clinical studies\, and translational approaches. In addition to his research and clinical leadership\, he plays an active educational role within the faculties of medicine and physiotherapy. He is a member of the Belgian Study Group of Multiple Sclerosis\, founding President of ParadigMS\, and serves on advisory boards for pharmaceutical companies active in MS research. In recognition of his scientific contributions\, he received an honorary award from the Flemish Government in 2019. \n\n\n\n \n\n\n\n            \n        \n        \n    \n\n\n\nAbstracts of the keynotes\nAnne-Catherine Chapelle (Belgium) – Seeing Optic Neuritis Through Optical Coherence Tomography: a new biomarker \n\n\n\nSince the revised McDonald criteria now include the optic nerve as a fifth topographical location\, careful and precise neuro-ophthalmologic examination has become mandatory. Accurate diagnosis of optic neuritis relies on a comprehensive assessment\, including optical coherence tomography (OCT). This technique enables precise\, non-invasive quantification of the peripapillary retinal nerve fiber layer and the ganglion cell layer. In this keynote\, we will review the evidence linking OCT findings to the diagnosis of optic neuritis\, visual outcomes\, and disease activity\, as well as its role in monitoring disease evolution. These data highlight the growing relevance of OCT in both clinical practice and research. \n\n\n\nAxel Petzold (UK) – Clinical Aspects of Optic Neuritis \n\n\n\nOptic neuritis (ON) is an inflammatory disorder of the optic nerve and a common cause of visual loss\, particularly in young and middle-aged adults. Clinically\, ON presents with subacute unilateral visual loss\, periocular pain exacerbated by eye movement\, impaired colour vision\, and visual field defects. Although many patients recover high-contrast visual acuity\, residual deficits in contrast sensitivity\, colour perception\, visual fields\, and visual fatigue are common. Clinically a common cause in a Caucasian population is multiple sclerosis (MS). Some clinical features such as bilateral involvement\, severe visual loss\, poor recovery\, or absence of pain should prompt urgent evaluation for other ON subgroups. \n\n\n\nThe clinical spectrum of ON is heterogeneous. MS-associated ON (MS-ON) remains frequent in neurological practise. IN MS-ON visual recovery is typically good. In contrast\, aquaporin-4 antibody-associated ON (AQP4-ON) is typically more severe\, may be bilateral\, and carries a high risk of permanent visual disability and future relapses. Myelin oligodendrocyte glycoprotein antibody-associated ON (MOG-ON) often presents with marked optic disc swelling and exquisite corticosteroid responsiveness. The relapse risk in MOG-ON varies\, with about half of all cases being monophasic. Accurate early phenotyping of ON is therefore central to prognosis and long-term management. \n\n\n\nDiagnosis is clinical\, supported by magnetic resonance imaging (MRI)\, serum antibody testing (AQP4-IgG and MOG-IgG)\, and optical coherence tomography (OCT). Acute management commonly includes high-dose corticosteroids to accelerate recovery\, with escalation therapies such as plasma exchange or IVIG considered in severe or refractory cases. Secondary prevention strategies depend on aetiology and relapse risk\, particularly in antibody-mediated disease and in patients at high risk of developing MS. \n\n\n\nBeyond acute treatment\, clinical care must address visual rehabilitation\, mental health burden\, and relapse surveillance. Persistent pain\, visual fatigue\, and anxiety about recurrence are frequent but under-recognised sequelae. Despite advances in immunotherapy and diagnostics\, substantial global variability remains in access to timely imaging\, antibody testing\, specialist care\, and relapse-preventive therapy. \n\n\n\nON is therefore both a neurological emergency and a window into systemic inflammatory disease. Optimising clinical outcomes requires early recognition\, aetiology-driven management\, structured follow-up\, and equitable access to specialist services. \n\n\n\n\nVenue: The Irish College\, Leuven\, and Parking details \n        \n            \n              \n                        \n                            Address of the venue\n                        \n                    \n                        \n                            About this Irish College\n                        \n                    \n                        \n                            About the parking\n                        \n                    \n            \n            \n                \n\n\nLocation: Paridaensinstituut \n\n\n\nAddress : Janseniusstraat 1\, 3000 Leuven \n\n\n\nTelephone  : 016 31 04 30 \n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\nThe Irish College Leuven was founded in 1607 and is one of the oldest Irish colleges on the European continent. It was established to educate Irish priests at a time when religious training was restricted in Ireland. Over the centuries\, the College became an important intellectual and cultural hub\, closely linked to the University of Leuven\, and played a key role in preserving Irish scholarship and heritage. Today\, it stands as a historical symbol of the long-standing academic and cultural ties between Ireland and Belgium. \n\n\n\n\n\nThe parking space is available near the venue. \n\n\n\nAccess & Parking \n\n\n\nBethlehem parking:  \n\n\n\nAddress : Redingenstraat 21\, 3000 Leuven (≈ 5-minute walk to Irish College) \n\n\n\nThe code for the parking will be provided prior to the event. \n\n\n\nGroup parking: Q-Park Heilig Hart \n\n\n\nAddress : Naamsestraat 102\, 3000 Leuven (≈ 10-minute walk to Irish College) \n\n\n\n \n\n\n\n            \n        \n        \n    \n\n\n\nFAQ \n\nHow can I register for the event?\nSimply click on REGISTRATION button you can see above this section and then select your admission ticket category \n\n\n\n\nCan I bring a guest?\nAbsolutely! You can register up to 5 persons per session\, if they are also healthcare professionals with a focus on neurology \n\n\n\n\nHow can I get updates or notifications about the event?\nStay connected with all updates and news by subscribing to the ParadigMS Foundation webpage: https://paradigms.foundation/ \n\n\n\n\nWill there be food and beverages provided?\nYes\, we provide a welcome coffee\, a coffee break and a networking lunch with a variety of drinks. \n\n\n\n\nWhat if I need to cancel my registration?\nIf you need to cancel your registration\, please send a message to learning@paradigms.foundation. \n\n\n\n\nIs there a dress code for the event?\nWe recommend wearing smart casual attire. \n\n\n\n\nWill the Annual MS meeting be live streamed?\nNo\, the live sessions of the meeting are not live streamed and available only for onsite participants. \n\n\n\n\nWho can I contact for additional information?\nIf you have any questions or need further information about either of the two learning experiences\, please feel free to reach out to us at learning@paradigms.foundation. \n\n\n\n\nWill there be a written report from the sessions?\nYes\, the ParadigMS Secretariat is planning to have a medical writer on site who will be tasked with producing a written report from both sessions. \n\n\n\n\nWill any of the sessions be recorded on video for later viewing?\nYes\, the keynotes will be video and audio recorded and will be made available on ParadigMS.foundation. You will need to create a Member account to have access to the recording (conditions to join as a member apply). \n\n\n\n\n\n\nSponsorships\nIn return for their sponsorship\, our sponsors receive visibility and can register a limited number of their staff to join the Meeting. Sponsors are not involved in the elaboration of the programme and presentations.  \n\n\n\n        \n            \n              \n                        \n                            Our gold sponsors\n                        \n                    \n                        \n                            Our bronze sponsors\n                        \n                    \n            \n            \n                \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n            \n        \n        \n    \n\n\nInterested to join as a sponsor? Please contact ParadigMS at secretariat@paradigms.foundation \n\n\n\n\n \n\n\n\n \n\n\n\nOrganized by
URL:https://paradigms.foundation/event/annual-ms-meeting-2026/
ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2025/12/AMS2026-PROD-banner-1080x655px-01.jpg
END:VEVENT
END:VCALENDAR